Imatinib mesylate in early chronic phase chronic myeloid leukemia: Experience from a developing country.
There are few publications on responses of patients with chronic phase chronic myeloid leukemia (CP-CML) from the Indian sub continent to imatinib mesylate (IM). This study analyses the response rates, progression free survival (PFS), overall survival and adverse events of early CP-CML patients on IM. Analysis of patients with untreated early CP-CML on IM from 2003 to 2006 was done. Standard criteria for hematological and cytogenetic responses were used. There were 201 patients with a median follow-up of 29.5 months. Thirty three percentage, 40% and 27% belonged to the low, intermediate and high-risk Hasford groups, respectively. Ninety seven percentage achieved complete hematological response. Fifty six percentage achieved complete cytogenetic response (CCR), 23% partial cytogenetic response, 17% minor response and 4% no response. The estimated PFS and OS at 29 months for the whole group was 77 and 94%, respectively. Hasford risk groups were predictive of CCR (p = 0.0018). None required permanent drug discontinuations due to adverse events. This study shows sub optimal outcomes to IM in early CP-CML. Late presentation may be one of the reasons for these outcomes. IM was well tolerated.
Rajappa
Senthil
S
Department of Medical Oncology, Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad, India.
Varadpande
Lalit
L
Paul
Tara
T
Jacob
Rachel
R
Digumarti
Raghunadharao
R
D000293:Adolescent; D000328:Adult; D000368:Aged; D001549:Benzamides; D003906:Developing Countries; D004341:Drug Evaluation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000068877:Imatinib Mesylate; D007194:India; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012074:Remission Induction; D012189:Retrospective Studies; D018570:Risk Assessment; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate